Taiho Pharmaceutical Co., Ltd. et al v. Eugia Pharma Specialities Ltd. et al
Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. |
Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities Ltd. and Aurobindo Pharma Ltd. |
1:2019cv02309 |
December 19, 2019 |
US District Court for the District of Delaware |
Colm F Connolly |
Patent - Abbreviated New Drug Application(ANDA) |
35 U.S.C. § 271 |
None |
Docket Report
This docket was last retrieved on August 15, 2023. A more recent docket listing may be available from PACER.
Document Text |
---|
Filing 12 ORDER, on or before February 27, 2020, counsel for plaintiffs shall inform the court as to whether the need for coordinated discovery and/or Markman proceedings is anticipated and, if so, when a joint scheduling conference might most efficiently be conducted. ORDER, Setting Deadlines: Notice of Compliance deadline set for 2/27/2020. Signed by Judge Colm F. Connolly on 1/27/2020. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(nmf) |
Pro Hac Vice Attorney Liane M. Peterson for Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(kmd) |
Pro Hac Vice Attorney Michael Kaminski for Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(kmd) |
Pro Hac Vice Attorney Bradley Roush for Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:19-cv-02368-CFC, 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC(mal) |
Filing 11 MOTION for Pro Hac Vice Appearance of Attorney Michael D. Kaminski, Liane M. Peterson, and Bradley Roush - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Mayo, Andrew) |
SO ORDERED, re (10 in 1:19-cv-02342-CFC, 11 in 1:19-cv-02309-CFC, 11 in 1:19-cv-02321-CFC, 11 in 1:19-cv-02368-CFC) MOTION for Pro Hac Vice Appearance of Attorney Michael D. Kaminski, Liane M. Peterson, and Bradley Roush filed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc. Signed by Judge Colm F. Connolly on 1/22/2020. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(fms) |
SO ORDERED, re #10 MOTION Seeking to Extend the Answer Deadlines of Defendants Eugia Pharma Specialities Ltd. and Aurobindo Pharma U.S.A., Inc. (UNOPPOSED) filed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc. Set/Reset Answer Deadlines: Aurobindo Pharma U.S.A., Inc. answer due 3/23/2020; Eugia Pharma Specialities Ltd. answer due 3/23/2020.. Signed by Judge Colm F. Connolly on 12/30/2019. (fms) |
Filing 10 MOTION Seeking to Extend the Answer Deadlines of Defendants Eugia Pharma Specialities Ltd. and Aurobindo Pharma U.S.A., Inc. (UNOPPOSED) - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Balick, Steven) |
Filing 9 WAIVER OF SERVICE returned executed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc.: For Aurobindo Pharma Ltd. waiver sent on 12/23/2019, answer due 3/23/2020. (Balick, Steven) |
Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC (rjb) |
Filing 8 SUMMONS Returned Executed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc.. Eugia Pharma Specialities Ltd. served on 12/20/2019, answer due 1/10/2020. (Balick, Steven) |
Filing 7 SUMMONS Returned Executed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc.. Aurobindo Pharma U.S.A., Inc. served on 12/20/2019, answer due 1/10/2020. (Balick, Steven) |
Summons Issued with Magistrate Consent Notice attached as to Aurobindo Pharma U.S.A., Inc. on 12/20/2019; Eugia Pharma Specialities Ltd. on 12/20/2019. (sam) |
No Summons Issued. (amf) |
Filing 6 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Otsuka Holdings Co., Ltd. for Taiho Oncology, Inc. - filed by Taiho Oncology, Inc. (amf) |
Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Otsuka Holdings Co., Ltd. for Taiho Pharmaceutical Co., Ltd. - filed by Taiho Pharmaceutical Co., Ltd. (amf) |
Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) RE46,284 E ;10,138,223 B2. (amf) |
Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 11/8/2019. Date of Expiration of Patent: SEE ATTACHED FORM.Thirty Month Stay Deadline: 3/23/2023. (amf) |
Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (amf) |
Filing 1 COMPLAINT FOR PATENT INFRINGEMENT - filed against Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., and Eugia Pharma Specialities Ltd. - Magistrate Consent Notice to Pltf. (Filing fee $ 400, receipt number 0311-2806679) - filed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc. (Attachments: #1 Exhibits A-C, #2 Civil Cover Sheet)(amf) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.